50,000 patients to reveal how new kidney drug works in real life
NCT ID NCT06278207
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This observational study will follow 50,000 people in Asia and the United States who have chronic kidney disease and type 2 diabetes and are already taking finerenone as part of their regular care. Researchers will collect data from electronic health records and insurance claims to understand patient characteristics, how the drug is used, and its safety and effectiveness in real-world conditions. No additional visits or tests are required.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Finerenone (Kerendia, Firialta)
What this could lead to
If successful, this study could provide a clearer picture of how finerenone works in everyday medical practice, helping doctors better understand its benefits and risks for people with kidney disease and diabetes.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by differences in patient care or data quality, and no new treatment is being tested.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Bayer
RECRUITINGBerlin, 13353, Germany
-
Many Locations
COMPLETEDMultiple Locations, New Jersey, 07981, United States
-
Many Locations
COMPLETEDMultiple Locations, Japan
-
Many Locations
COMPLETEDMultiple Locations, Taiwan